Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239681 · ClinicalTrials.gov registry record · Phase 3
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17,802
- Enrollment target
NCT00239681: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT00239681 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 17,802 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2209% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00239681, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17,802 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.
Primary Outcome
Days from randomization to the first of CV death, stroke, MI, hospitalization for unstable angina or arterial revascularization. If no event, censoring occurs at earliest of termination date or efficacy cut-off date of 30 Mar 2008. Events were adjudicated by an endpoint committee. Kaplan-Meier estimate of the mean
Interventions
- OTHER Placebo
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,802 participants |
| Start Date | 2003-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Why NCT00239681 stopped before completion
NCT00239681 is an interventional study that assigns participants to a tested intervention. Its 17,802 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2209% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00239681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00239681 about?
NCT00239681 is a clinical study titled "JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events". The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.
What is the current status of trial NCT00239681?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17,802 participants. The study started on 2003-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00239681?
The interventions under investigation include: Placebo (OTHER), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00239681?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00239681's enrollment target sits among peer trials
17,802 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07108660 · 17,800 participants · NA
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia